Molecular-genetic approach to predicting the effectiveness of aggressive non-Нodgkin's lymphomas therapy
Author Affiliations1Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
2Institute for Internal and Preventive Medicine of SB RAMS 630090, Novosibirsk, Boris Bogatkov str., 175/1
3Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
4Novosibirsk State Medical University of Miszdrav of Russia 630091, Novosibirsk, Krasny av., 52
5Novosibirsk State Medical University of Minzdrav of Russia 630091, Novosibirsk, Krasny av., 52
Abstract
Purpose: to study the effectiveness of therapy of patients with aggressive non-Hodgkin's lymphoma receiving immunochemotherapy, depending on the genotype of rs1625895. The survey group consists of 41 patients with high grade B-cell non-Hodgkin's lymphomas diagnosed in the Novosibirsk City Hematology Center from 2004 to 2007. All patients underwent the therapy with the rituximab. In the general group of patients remission was obtained in 59 % of cases, 5-year overall survival rate was 36.6 %, disease-free - 24.4 %. In the subgroup of patients with the genotype G/G rs1625895 remission was obtained in 42.9 % of people. It was statistically significant (p = 0.003) lower than in the subgroup of patients with the genotype G/A and A/A - 92.3 %. The statistically significant association of genotype G/G with deterioration in the overall (21.4 %) and disease-free survival (10.7 %) vs. 69.2 % (p = 0.004) and 53.9 % (p = 0.0006) with genotype G/A and A/A respectively has been shown.
Key words
References1. Voropaeva E.N., Voevoda M.I., Pospelova T.I., Maximov V.N. Intronic polymorphisms antioncogene TP53 in patients of older age group with indolent non-Hodgkin's malignant lymphomas entities // Uspekhi gerontologii. 2013. 26. (2). 258-262. (in Russian)
2. Gorshkova E.V., Kaledin V.I., Kobzev V.F., Merkulov T.I. Lung cancer-associated SNP at the beginning of mouse K-ras gene intron 2 is essential for transcription factor binding // Byulleten' eksperimental'noy biologii i meditsiny. 2006. 141. (6). 731-733.(in Russian)
3. Kopnin B.P., Kopnin P.B., Chromova N.V., Agapov L.S. The many faces of p53: a variety of forms, functions and oncosupressiv oncogenic activities // Gematologiya. 2008. 1. (1). 53-68. (in Russian)
4. Savchenko V.G. Software treatment of diseases of the blood system: The collection of algorithms and protocols for diagnosis of diseases of the blood system / Ed. V.G. Savchenko. Moscow: Praktika, 2012. 1056 p. (in Russian)
5. Biros E., Kohъt A., Biros I. et al. A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients // Lung Cancer. 2002. 35. (3). 231-235.
6. De Feo E., Persiani R., La Greca A. et al. A case-control study on the effect of p53 and p73 polymorphisms on gastric cancer risk and progression // Mutat. Res. 2009. 675. (1-2). 60-65.
7. Gallм P., Cadoni G., Volante M. et al. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population // BMC Cancer. 2009. 9. 137.
8. Kochethu G., Delgado J., Pepper C. et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia // Leuk. Res. 2006. 30. (9). 1113-1118.
9. Mavridou D., Gornall R., Campbell I.G. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer // Br. J. Cancer. 1998. 77. (4). 676-678.
10. Mechanic L.E., Bowman E.D., Welsh J.A. et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors // Cancer Epidemiol. Biomarkers Prev. 2007. 16. 214-222.
11. Outcomes of cancer treatment of technology assessment and cancer treatment guidelines // J. Clin. Oncol. 1996. 14. (3). 671-679.
12. Pangilinan F., Geiler K., Dolle J. et al. Construction of a high resolution linkage disequilibrium map to evaluate common genetic variation in TP53 and neural tube defect risk in an Irish population // Am J. Med. Genet. A. 2008. 146A. (20). 2617-2625.
13. Peller S. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility // DNA Cell. Biol. 1995. 14. (12). 983-990.
14. Sabbatini E., Bacci F., Sagramoso C., Pileri S.A. WHO classification of tumors of haematopoietic and lymphoid tissues in 2008: an overview // Pathologica. 2010. 102. (3). 83-87.
15. Sauka C., Kohъt A., Kundrбt I., Janнk M. Polymorphism of gene p53 and apoptosis in patients with malignant lung disease-our observation // Clin. Oncol. 2008. 21. (3). 98-103.
16. Sehn L.H., Berry B., Chhanabhai M. et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP // Blood. 2007. 109. (5). 1857-1861.
17. Sribudiani Y., Metzger M., Osinga J. et al. Variants in RET associated with Hirschsprung's disease affect binding of transcription factors and gene expression // Gastroenterology. 2011. 20. (2). 572-582.
About Authors (Correspondence):
Voropaeva E.N. - candidate of medical sciences, researcher of the laboratory of molecular-genetic study methods of the therapeutic diseases, е-mail: vena.81@mail.ru
Voevoda M.I. - corresponding member of the RAMS, doctor of medical sciences, professor, director
Pospelova T.I. - doctor of medical sciences, professor, head of the chair for therapy, hematology and transfusiology, е-mail: postatgem@mail.ru
Beresina O.V. - candidate of medical sciences, assistant professor of the chair for therapy, hematology and transfusiology, е-mail: ovberezina@mail.ru
Maksimov V.N. - doctor of medical sciences, professor, head of the laboratory of molecular-genetic study methods of the therapeutic diseases, е-mail: medik11@mail.ru
Full Text
